Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: J07BB02

Adjupanrix (previously Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals)(split influenza virus, inactivated, containing antigen: A/VietNam/1194/2004 (H5N1) like strain used (NIBRG-14))

Influenza, Human;Immunization;Disease Outbreaks

Marketing Authorisation Holder: GlaxoSmithKline Biologicals S.A.

EMA Authorisation: 10/10/2009

INN: pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted)

Indication

Prophylaxis of influenza in an officially declared pandemic situation. Pandemic influenza vaccine should be used in accordance with official guidance.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Adjupanrix (previously Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals) — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Ask about Adjupanrix (previously Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals)Create Free Account

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.